Redeye notes that Doro's Q1 2023 performance was somewhat weaker than anticipated, but there are indications of positive developments in the underlying business. Doro's emphasis on boosting R&D and sales initiatives may impact margins in the short term, but we believe that the company is on the path to returning to profitable growth in the coming years.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/